Neuronetics (STIM) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
August 8, 2023 7:30 AM EDTMALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the Company or Neuronetics) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2023.
Second Quarter 2023 Highlights
Second quarter 2023 revenue of $17.6 million, an increase of 8% over the second quarter of 2022U.S. treatment session revenue increased 9% over the second quarter of 2022Shipped 54... More